Moderna, Inc.
$55.11
▲
1.62%
2026-04-22 10:12:13
www.modernatx.com
NMS: MRNA
Explore Moderna, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$21.94 B
Current Price
$55.11
52W High / Low
$59.55 / $22.28
Stock P/E
—
Book Value
$21.95
Dividend Yield
—
ROCE
-29.7%
ROE
-28.87%
Face Value
—
EPS
$-7.25
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
4,700
Beta
1.34
Debt / Equity
15.09
Current Ratio
3.29
Quick Ratio
3.22
Forward P/E
-10.96
Price / Sales
10.4
Enterprise Value
$15.63 B
EV / EBITDA
-5.47
EV / Revenue
8.04
Rating
Hold
Target Price
$45.15
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Nkarta, Inc. | $3.49 | — | $247.38 M | — | -31.94% | -28.9% | $3.48 / $1.63 | $4.39 |
| 2. | Rigel Pharmaceuticals, Inc. | $32.49 | 1.65 | $604.16 M | — | 30.28% | 1.86% | $52.24 / $16.11 | $21.38 |
| 3. | Artiva Biotherapeutics, Inc. | $13.39 | — | $310.19 M | — | -76.21% | -56.55% | $13.2 / $1.47 | $4.53 |
| 4. | Prelude Therapeutics Incorporated | $4.51 | — | $279.73 M | — | -118.39% | -99.45% | $5.54 / $0.72 | $0.83 |
| 5. | Karyopharm Therapeutics Inc. | $8.94 | — | $193.06 M | — | -554.58% | 81.86% | $10.99 / $3.65 | $-16 |
| 6. | OKYO Pharma Limited | $1.59 | — | $85.27 M | — | 127.79% | 82.36% | $3.35 / $1.11 | $-0.09 |
| 7. | IDEAYA Biosciences, Inc. | $33.6 | — | $2.95 B | — | -15.17% | -10.92% | $39.28 / $16.07 | $11.65 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 676 M | 1 B | 137 M | 107 M | 956 M | — |
| Operating Profit | -857 M | -260 M | -907 M | -1.05 B | -1.25 B | — |
| Net Profit | -826 M | -200 M | -825 M | -971 M | -1.12 B | — |
| EPS in Rs | -2.08 | -0.5 | -2.08 | -2.45 | -2.82 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 1.92 B | 3.2 B | 6.75 B | 18.88 B |
| Operating Profit | -3.07 B | -3.94 B | -4.24 B | 9.42 B |
| Net Profit | -2.82 B | -3.56 B | -4.71 B | 8.36 B |
| EPS in Rs | -7.12 | -8.98 | -11.89 | 21.08 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 12.34 B | 14.14 B | 18.43 B | 25.86 B |
| Total Liabilities | 3.69 B | 3.24 B | 4.57 B | 6.74 B |
| Equity | 8.65 B | 10.9 B | 13.85 B | 19.12 B |
| Current Assets | 6.54 B | 8.1 B | 10.32 B | 13.43 B |
| Current Liabilities | 1.99 B | 2.21 B | 3.02 B | 4.92 B |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -1.87 B | -3 B | -3.12 B | 4.98 B |
| Investing CF | 1.95 B | 1.95 B | 4.21 B | -5.18 B |
| Financing CF | 593 M | 56 M | -1.38 B | -3.45 B |
| Free CF | -2.08 B | -4.05 B | -3.83 B | 4.58 B |
| Capex | -202 M | -1.05 B | -707 M | -400 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -52.64% | -64.22% | — | — |
| Earnings Growth % | 24.46% | -156.37% | — | — |
| Profit Margin % | -111.32% | -69.8% | 44.3% | — |
| Operating Margin % | -123.32% | -62.76% | 49.91% | — |
| Gross Margin % | 54.24% | 30.52% | 71.31% | — |
| EBITDA Margin % | -106.1% | -53.57% | 51.75% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.